Companion diagnostics is a relatively new branch of diagnostics that is expected to grow at a swift pace in the near future. The various advantages it offers have increased its market demand globally. It has the potential to totally alter the drug development process and commercialization of the drug prospects will generate drugs with a better therapeutic efficiency in a faster and cost-effective way.
Oncology is one such area that has hugely benefitted from the advent of companion diagnostics. Companion diagnostics has been highly beneficial to identify patients with specific biomarkers that have predictive responses. This means that it has the power to predict the response of a specific therapy for a specific person, which in turn results in better patient treatments and reduction in healthcare expenditure.
Global Companion Diagnostics Market- Market Dynamics
The fact that companion diagnostics can offer targeted therapies (personalized medicine) depending on the disease makes it an exciting field and a market to watch out for. Global market players have identified it as a huge revenue-generating technology that can offer better therapeutic efficiency in a lesser time frame than the normal ones and have started to invest heavily into developing novel targeted therapies for diseases.
Some of the many factors driving the growth of the companion diagnostics market are:
Improved efficacy/safety profiles of drugs
Accelerated drug regulatory approvals
Reduced healthcare expenditure and drug development costs
Increasing partnerships between market players, government organizations and other research firms over the use of companion diagnostics
Emergence of new pharmaceuticals and diagnostics.
While the global companion diagnostics market offers ample scope for growth, there are certain factors restraining it. These include:
Complex clinical trial procedures
Intellectual property issues in certain areas
Currently, North America is the largest market for companion diagnostics on the global scale. This is a result of the technological advances, increased adoption rates, and higher awareness levels among the population about the potential benefits of companion diagnostics. However, Asia-Pacific and Latin America can be considered as the fastest growing segments of the global market. This is due to the increased chronic disease population, lenient regulatory framework and cost-effective clinical trial procedures in these markets.
The global companion diagnostics market can be segmented on the basis of indication and geography. On the basis of indication, the market has been segmented into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia and others. On the basis of geography, the market has been segmented into North America, Europe, Asia-Pacific and Rest of the World.
The report gives a competitive intelligence analysis in the form of mergers and acquisition activity, collaborations, agreements, new product launches, along with the profiles of major players including the likes of-
This Report Offers:
Market definition for the global companion diagnostics market along with identification of key drivers and restraints for the market.
Market analysis for the companion diagnostics market with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the global companion diagnostics market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1.1 Report Description
1.2 Research Methodology
2. Companion Diagnostics Market Overview
2.1 Companion Diagnostics Introduction
2.1.1 Context and Background
2.1.2 Difference between In Vitro Diagnostics and Companion Diagnostics
2.1.3 Labeling Considerations
2.1.4 Classical Drug & In Vitro Diagnostics Development
2.1.5 Companion Diagnostics Regulatory Framework
220.127.116.11 United States Regulation
18.104.22.168 Europe Regulation
3. Global Companion Diagnostics Market Dynamics
3.1 Market Drivers
3.1.1 Emerging Pharmaceutical and Diagnostic Companies
3.1.2 Rising incidence of cancer cases leading to increased demand for cancer treatments
3.1.3 Improved Safety/Efficacy Profile of Drug
3.1.4 Increasing Drug Development Costs
3.1.5 Accelerated Drug Regulatory Approval
3.2 Market Restraints
3.2.1 Complex Clinical Trial Execution
3.2.2 Intellectual Property Issues
3.2.3 Reimbursement Issues
3.3.1 Research Investment
3.3.2 Emerging Treatment Breakthroughs
3.3.3 Shorter Development Timelines
3.3.4 Superior Market Penetration
4. Global Companion Diagnostics Market, By Indication
4.1.1 Global Companion Diagnostics Market, By Indication, 2014-2020
4.2 Lung Cancer
4.2.1 Lung Cancer Companion Diagnostics Market, 2014-2020
4.3 Breast Cancer
4.3.1 Breast Cancer Companion Diagnostics Market, 2014-2020
4.4 Colorectal Cancer
4.4.1 Colorectal Cancer Companion Diagnostics Market, 2014-2020
4.5.1 Melanoma Companion Diagnostics Market, 2014-2020
4.6.1 Leukemia Companion Diagnostics Market, 2014-2020
4.7 Others (Brain Cancer, Gastric Cancer, Prostate Cancer)
5. Companion Diagnostics Market, by Geography
5.1.1 Global Companion Diagnostics Market, by Geography, 2014-2020
5.1.2 Companion Diagnostics Market Comparative Analysis, by Geography, 2014-2020
5.2 North America
5.2.1 North America Companion Diagnostics Market, 2014-2020
22.214.171.124 United States
5.3.1 Europe Companion Diagnostics Market, 2014-2020
126.96.36.199 United Kingdom
5.4.1 Asia-Pacific Companion Diagnostics Market, 2014-2020
5.5.1 RoW Companion Diagnostics Market, by Type, 2014-2020
6. Companion Diagnostics Market Share Analysis
6.1 Key Players Global Market Share Analysis
6.1.1 Global Companion Diagnostics Market Share Analysis, by Key Players, 2013
6.1.2 Global Companion Diagnostics Market, Key Players by Segment
7. Competitive Landscape
7.1 New Product Innovations
7.2 Agreements, Partnerships, Joint Ventures and Collaborations
7.3 Mergers & Acquisitions
7.4 Regulatory Authorities
8. Company Profiles
8.1 A&G Pharmaceutical, Inc.
8.2 Abbott Diagnostics
8.3 Biocrates Life Sciences AG
8.4 Clovis Oncology, Inc.
8.5 Dako A/S
8.6 EKF Diagnostics Holdings plc.
8.7 Eli Lilly and Company
8.8 Eutropics Pharmaceuticals, Inc.
8.9 Daan Diagnostics Ltd.
8.10 Foundation Medicine, Inc.
8.11 Genentech, Inc.
8.12 Intezyne, Inc.
8.13 Leica Biosystems GmbH
8.14 Myriad Genetics, Inc.
8.15 NEOMICS Co., Ltd.
8.16 NuCana Biomed Limited
8.17 Oxford Biodynamics Limited
8.18 Qiagen N.V.
8.19 Roche Diagnostics Limited
8.20 Siemens Healthcare Diagnostics Inc.
8.21 Skuldtech France
8.22 Takeda Pharmaceuticals International GmbH
8.23 TheraDiag SA
8.24 Thermo Fisher Scientific Inc.
8.25 Tocagen Inc.
8.26 Ventana Medical Systems, Inc.